The approach, which originated in Portugal, reprogrammes tumour cells to trigger an immune response against the tumour itself. Clinical trials in humans are scheduled for 2027.
A Portuguese researcher working in Sweden, Fábio Rosa, has received the 2026 Innovation and Science Award from the Danish Institute of Bioinnovation for his work on developing a new cancer therapy that turns tumours into their own vaccines.
In other words, the approach involves reprogramming tumour cells to trigger anti-tumour immunity.
A Portuguese researcher working in Sweden, Fábio Rosa, has received the 2026 Innovation and Science Award from the Danish Institute of Bioinnovation for his work on developing a new cancer therapy that turns tumours into their own vaccines.
In other words, the approach involves reprogramming tumour cells to trigger anti-tumour immunity.
